APTEVO THERAPEUTICS INC (APVO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.27-7.30%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · APVO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The Company continues to evaluate clinical activity, safety and tolerability in RAINIER and expects to complete the current study by year-end 2026, conduct regulatory interactions and initiate Phase…
Stated in 3 of 3 supplied quarters. Management reported: “The Company continues to evaluate clinical activity, safety and tolerability in RAINIER and expects to complete the current study by year-end 2026, conduct regulatory interactions and initiate Phase 2 development in 2027.” “RAINIER has entered the final stage of dose optimization, positioning Aptevo to complete the Phase 1b RAINIER trial and select the recommended Phase 2 dose this year in anticipation of a Phase 2 regulatory interaction in 1Q27.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“The Company continues to evaluate clinical activity, safety and tolerability in RAINIER and expects to complete the current study by year-end 2026, conduct regulatory interactions and initiate Phase…”
“RAINIER has entered the final stage of dose optimization, positioning Aptevo to complete the Phase 1b RAINIER trial and select the recommended Phase 2 dose this year in anticipation of a Phase 2 regu…”
“RAINIER trial on track for completion and Phase 2 dose selection by year end.”
This work includes advancing APVO451, a targeted trispecific immunotherapy candidate for solid tumors, and a strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology p…
Stated in 2 of 3 supplied quarters. Management reported: “Non-Dilutive Grant Funding Advances APVO451 and Validates Trispecific Solid Tumor Strategy Aptevo secured a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment (CARE) Fund to support investigational new drug (IND)-enabling work for APVO451, a nectin-4-targeted trispecific immunotherapy candidate for solid tumors.” “Together, the grant and planned development timeline position APVO451 as an emerging pipeline value driver, with development candidate selection targeted by year-end 2026 and IND-enabling studies planned for the first quarter of 2027.”
“This work includes advancing APVO451, a targeted trispecific immunotherapy candidate for solid tumors, and a strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology p…”
“Non-Dilutive Grant Funding Advances APVO451 and Validates Trispecific Solid Tumor Strategy Aptevo secured a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment (CARE…”
This work includes advancing APVO451, a targeted trispecific immunotherapy candidate for solid tumors, and a strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology p…
Stated in 2 of 3 supplied quarters. Management reported: “• $1.5 million non-dilutive award to support APVO451 IND-enabling work • Competitive, merit-reviewed grant provides third-party validation for APVO451’s tumor-directed trispecific approach • Development candidate selection targeted by year-end 2026, with IND-enabling studies planned for the first quarter of 2027 Strategic Niowave Collaboration Opens a New Radiopharmaceutical Development Opportunity Aptevo expanded its development strategy through a 50/50 collaboration with Niowave to develop up to three radiopharmaceutical oncology programs.” “Niowave also made an at-the-market equity investment in Aptevo at closing, creating additional alignment between the companies.”
“This work includes advancing APVO451, a targeted trispecific immunotherapy candidate for solid tumors, and a strategic collaboration with Niowave to develop up to three radiopharmaceutical oncology p…”
“• $1.5 million non-dilutive award to support APVO451 IND-enabling work • Competitive, merit-reviewed grant provides third-party validation for APVO451’s tumor-directed trispecific approach • Developm…”
• 50/50 collaboration to develop up to three radiopharmaceutical oncology programs • Strategic equity investment by Niowave at closing, representing an initial 7.9% ownership position, with the poten…
Stated in 2 of 3 supplied quarters. Management reported: “• 50/50 collaboration to develop up to three radiopharmaceutical oncology programs • Strategic equity investment by Niowave at closing, representing an initial 7.9% ownership position, with the potential to build up to 19.99% • Opportunity to extend Aptevo’s tumor-targeting approach into radiopharmaceutical therapeutics for difficult-to-treat cancers Q2 2026 Financial Position Aptevo had cash and cash equivalents totaling $9.8 million as of June 30, 2026.” “Enhanced Financial Flexibility Supports Upcoming Catalysts During the quarter, Aptevo secured a $60 million SEPA, providing meaningful access to capital and extending financial flexibility as the company advances toward planned milestones.”
“• 50/50 collaboration to develop up to three radiopharmaceutical oncology programs • Strategic equity investment by Niowave at closing, representing an initial 7.9% ownership position, with the poten…”
“Enhanced Financial Flexibility Supports Upcoming Catalysts During the quarter, Aptevo secured a $60 million SEPA, providing meaningful access to capital and extending financial flexibility as the com…”
Complete RAINIER dose optimization, select a Phase 2 dose, and pursue the planned regulatory interaction for mipletamig in frontline AML.
Over the trailing year it converted 1.02x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
26 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.